摘要
目的评价盐酸吡格列酮对2型糖尿病治疗的疗效和安全性。方法采用自身前后对照研究,纳入首次诊断为2型糖尿病且经饮食运动治疗三月以上或接受除噻唑烷二酮以外其它口服降糖药物治疗,剂量稳定三个月以上而血糖控制不满意的2型糖尿病患者84例,予盐酸吡格列酮30mg每日一次口服,疗程12周。已口服符合入选要求降糖药患者,联合并维持原有剂量的口服降糖药物治疗至随访结束。在试验开始和结束日,测量体重指数(BMI)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、空腹胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血红蛋白(Hb)、糖化血红蛋白(HbA1c),计算胰岛素抵抗指数(HOMA-IR)。对治疗前后上述指标进行对比分析。结果 81例患者完成完成全疗程治疗,平均病程(3.24±3.95)年;12周时FPG、HbA1c、FINS、HOMA-IR、SBP、DBP、TG、Hb均较治疗前基线时分别下降,HDL较治疗前基线时上升(1.11±0.29mmol/L比1.27±0.32 mmol/L,P<0.05);治疗期间不良反应少,大多未做特殊处理而自行好转。结论盐酸吡格列酮能改善胰岛素抵抗,有效降2型糖尿病患者的血糖水平,调节血脂,不良反应少,是一种安全有效的降糖药物。
Objective To observe the effect and safety of pioglitazone hydrochloride in patients with type 2 diabetes mellitus.Methods Patients with type 2 diabetes mellitus were treated with pioglitazone hydrochloride.84 cases of them without controlling the serum glucose were treated with pioglitazone,additionally.BMI,SBP,DBP,FPG,FINS,TC,TG,HDL-C,LDL-C,Hb and HbA1c were measured.HOMA-IR was used for evaluating insulin resistance.All side effects were recorded.Results 81 patients finished the trial course.FPG,HbA1c,FINS,HOMA-IR,SBP,DBP,TG and Hb were significantly decreased 12 months after treatment.HDL was significantly increased（1.11±0.29 mmol/L vs 1.27±0.32 mmol/L,P0.05）12 months after treatment.There were few adverse reactions during the therapeutic process.Conclusion Pioglitazone hydrochloride can effectively improve insulin resistance and decrease blood glucose level in type 2 diabetes mellitus.
出处
《西部医学》
2011年第2期345-347,共3页
Medical Journal of West China
关键词
吡格列酮
胰岛素抵抗
2型糖尿病
Pioglitazone
Insulin resistance
Type 2 diabetes mellitus
